Prohibits pharmacy benefits managers from operating pharmacy practice sites directly or indirectly.
This bill would prohibit pharmacy benefits managers (PBMs) from directly or indirectly owning, controlling, or holding a permit to operate a pharmacy practice site in New Jersey. Beginning July 1, 2027, a PBM could no longer have a direct or indirect interest in a pharmacy permitted under the New Jersey Pharmacy Practice Act. The bill is aimed at separating PBMs from retail pharmacy operations to reduce conflicts of interest and address concerns that vertically integrated PBM-owned pharmacies can disadvantage independent pharmacies and affect drug pricing and patient choice.
The bill also creates a limited exception for rare, orphan, or limited-distribution drugs that may otherwise be unavailable in the market. In those cases, the State Board of Pharmacy may issue a special permit, or convert an existing permit to a special permit, for a temporary period of at least 90 days, with the special-permit authority expiring September 1, 2028. The board is directed to adopt rules for notice, application, timing, and emergency determinations related to these special permits.
The bill would amend the regulatory framework governing pharmacy practice sites under the New Jersey Pharmacy Practice Act by barring PBMs from owning or controlling permitted pharmacies and by requiring the State Board of Pharmacy to deny, revoke, or refuse renewal of permits that violate the new restriction. It also imposes transition duties on the board and affected pharmacies, including an initial assessment of existing permits, advance notice to potentially affected pharmacies, and patient/provider notification requirements before the effective date of the ownership ban. The measure would primarily affect PBMs, vertically integrated pharmacy chains, independent pharmacies, patients who use specialty or limited-distribution drugs, and the State Board of Pharmacy.
The bill’s stated purpose and legislative findings reflect a strongly pro-consumer and pro-independent-pharmacy sentiment, emphasizing patient access, fair prices, and the need to curb anticompetitive conduct. The available context does not include committee testimony or recorded votes, so there is no documented opposition or support from hearings in the provided materials. Based on the text alone, the bill appears designed to address concerns about market concentration and conflicts of interest in the pharmacy sector.
The main point of contention is likely the bill’s prohibition on PBMs operating pharmacies, which could be viewed by supporters as a necessary conflict-of-interest safeguard and by opponents as an overbroad restriction on integrated care and business operations. A second area of concern is the potential effect on access to specialty medications, which the bill addresses through a temporary special-permit exception for rare, orphan, or limited-distribution drugs. The transition timeline, permit revocation process, and notice obligations may also be disputed by affected PBMs and pharmacy operators because they require significant operational changes before the July 1, 2027 effective date.